1
|
Brock J, Sale A, Jayaraju U, Chandetreya A, Lee P. A cost-consequence analysis of eLearning videos designed to supplement the consent process in lower limb arthroplasty. Ann R Coll Surg Engl 2023; 105:278-282. [PMID: 36260293 PMCID: PMC9974341 DOI: 10.1308/rcsann.2022.0100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2022] [Indexed: 03/02/2023] Open
Abstract
INTRODUCTION Since the Montgomery ruling in 2015 surgeons have been tasked with identifying material risk when taking informed consent. Despite this, there has been limited uptake of technological aids to supplement the consent process although such aids are shown to improve patient knowledge and satisfaction. ConsentPLUS is a free-to-access website with bite-sized educational videos designed to clearly explain lower limb arthroplasty procedures to patients and aid their consent. METHODS The authors performed a prospective cost-consequence analysis, outlining any costs associated with the intervention and any quantitative or qualitative impacts the intervention may have on patients. RESULTS A total of 3,143 consecutive patients were identified who were undergoing total knee or hip replacement in 25 elective NHS orthopaedic units. The total cost of development and projected 10-year running fees for ConsentPLUS total £75,000. Health Foundation support means the service is free-to-access for centres throughout the UK. Mean exposure time per patient was 10min 29s, equivalent to £185,437 of additional contact time according to the National Tariff. Mean clinic time was reduced by 17min owing to the earlier identification of material risk. Patient knowledge on pre- and post-video quizzes increased from 7.01 to 9.08 following eLearning (paired t-test = 0.998). The process had an overall satisfaction rate of 97%. CONCLUSION Educational eLearning videos are an accessible and digestible way to supplement the consent process. This enables earlier identification of material risk in clinics owing to improved patient knowledge, leading to increased patient satisfaction with arthroplasty consenting.
Collapse
Affiliation(s)
| | | | | | | | - P Lee
- Cwm Taf Morgannwg University Health Board, UK
| |
Collapse
|
2
|
Waliullah S, Fonsah EG, Brock J, Li Y, Ali ME. First Report of Crown Rot of Banana Caused by Fusarium proliferatum in Georgia, U.S.A. Plant Dis 2022; 106:1526. [PMID: 34705491 DOI: 10.1094/pdis-08-21-1809-pdn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- S Waliullah
- Department of Plant Pathology, University of Georgia, Tifton, GA 31793
| | - E G Fonsah
- Department of Agricultural & Applied Economics, University of Georgia, Tifton, GA 31793
| | - J Brock
- Department of Plant Pathology, University of Georgia, Tifton, GA 31793
| | - Y Li
- Agricultural College, Northeast Agricultural University, Harbin 150030, P.R. China
| | - M E Ali
- Department of Plant Pathology, University of Georgia, Tifton, GA 31793
| |
Collapse
|
3
|
Xiong W, Gasparian A, Gao H, Dutta D, Khandaker M, Liyanage N, Pasyuk E, Peng C, Bai X, Ye L, Gnanvo K, Gu C, Levillain M, Yan X, Higinbotham DW, Meziane M, Ye Z, Adhikari K, Aljawrneh B, Bhatt H, Bhetuwal D, Brock J, Burkert V, Carlin C, Deur A, Di D, Dunne J, Ekanayaka P, El-Fassi L, Emmich B, Gan L, Glamazdin O, Kabir ML, Karki A, Keith C, Kowalski S, Lagerquist V, Larin I, Liu T, Liyanage A, Maxwell J, Meekins D, Nazeer SJ, Nelyubin V, Nguyen H, Pedroni R, Perdrisat C, Pierce J, Punjabi V, Shabestari M, Shahinyan A, Silwal R, Stepanyan S, Subedi A, Tarasov VV, Ton N, Zhang Y, Zhao ZW. A small proton charge radius from an electron-proton scattering experiment. Nature 2019; 575:147-150. [PMID: 31695211 DOI: 10.1038/s41586-019-1721-2] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 09/19/2019] [Indexed: 11/09/2022]
Abstract
Elastic electron-proton scattering (e-p) and the spectroscopy of hydrogen atoms are the two methods traditionally used to determine the proton charge radius, rp. In 2010, a new method using muonic hydrogen atoms1 found a substantial discrepancy compared with previous results2, which became known as the 'proton radius puzzle'. Despite experimental and theoretical efforts, the puzzle remains unresolved. In fact, there is a discrepancy between the two most recent spectroscopic measurements conducted on ordinary hydrogen3,4. Here we report on the proton charge radius experiment at Jefferson Laboratory (PRad), a high-precision e-p experiment that was established after the discrepancy was identified. We used a magnetic-spectrometer-free method along with a windowless hydrogen gas target, which overcame several limitations of previous e-p experiments and enabled measurements at very small forward-scattering angles. Our result, rp = 0.831 ± 0.007stat ± 0.012syst femtometres, is smaller than the most recent high-precision e-p measurement5 and 2.7 standard deviations smaller than the average of all e-p experimental results6. The smaller rp we have now measured supports the value found by two previous muonic hydrogen experiments1,7. In addition, our finding agrees with the revised value (announced in 2019) for the Rydberg constant8-one of the most accurately evaluated fundamental constants in physics.
Collapse
Affiliation(s)
- W Xiong
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - A Gasparian
- North Carolina A&T State University, Greensboro, NC, USA.
| | - H Gao
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - D Dutta
- Mississippi State University, Mississippi State, MS, USA.
| | | | - N Liyanage
- University of Virginia, Charlottesville, VA, USA
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - C Peng
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - X Bai
- University of Virginia, Charlottesville, VA, USA
| | - L Ye
- Mississippi State University, Mississippi State, MS, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, VA, USA
| | - C Gu
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - M Levillain
- North Carolina A&T State University, Greensboro, NC, USA
| | - X Yan
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - M Meziane
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - Z Ye
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA.,Argonne National Laboratory, Lemont, IL, USA
| | - K Adhikari
- Mississippi State University, Mississippi State, MS, USA
| | - B Aljawrneh
- North Carolina A&T State University, Greensboro, NC, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, MS, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi State, MS, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - V Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - D Di
- University of Virginia, Charlottesville, VA, USA
| | - J Dunne
- Mississippi State University, Mississippi State, MS, USA
| | - P Ekanayaka
- Mississippi State University, Mississippi State, MS, USA
| | - L El-Fassi
- Mississippi State University, Mississippi State, MS, USA
| | - B Emmich
- Mississippi State University, Mississippi State, MS, USA
| | - L Gan
- University of North Carolina, Wilmington, NC, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov, Ukraine
| | - M L Kabir
- Mississippi State University, Mississippi State, MS, USA
| | - A Karki
- Mississippi State University, Mississippi State, MS, USA
| | - C Keith
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Kowalski
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - I Larin
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow, Russia.,University of Massachusetts, Amherst, MA, USA
| | - T Liu
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | | | - J Maxwell
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | | | - V Nelyubin
- University of Virginia, Charlottesville, VA, USA
| | - H Nguyen
- University of Virginia, Charlottesville, VA, USA
| | - R Pedroni
- North Carolina A&T State University, Greensboro, NC, USA
| | - C Perdrisat
- College of William and Mary, Williamsburg, VA, USA
| | - J Pierce
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - V Punjabi
- Norfolk State University, Norfolk, VA, USA
| | - M Shabestari
- Mississippi State University, Mississippi State, MS, USA
| | | | - R Silwal
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Subedi
- Mississippi State University, Mississippi State, MS, USA
| | - V V Tarasov
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow, Russia
| | - N Ton
- University of Virginia, Charlottesville, VA, USA
| | - Y Zhang
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - Z W Zhao
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| |
Collapse
|
4
|
Roy P, Park S, Crede V, Anisovich AV, Klempt E, Nikonov VA, Sarantsev AV, Wei NC, Huang F, Nakayama K, Adhikari KP, Adhikari S, Angelini G, Avakian H, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Boiarinov S, Briscoe WJ, Brock J, Brooks WK, Burkert VD, Cao F, Carlin C, Carman DS, Celentano A, Chatagnon P, Chetry T, Ciullo G, Cole PL, Contalbrigo M, Cortes O, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Deur A, Diehl S, Djalali C, Dugger M, Dupre R, Duran B, Egiyan H, Ehrhart M, El Alaoui A, El Fassi L, Eugenio P, Fegan S, Filippi A, Fradi A, Gilfoyle GP, Girod FX, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hafidi K, Hanretty C, Harrison N, Hattawy M, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Johnston S, Joosten S, Kabir ML, Keith CD, Keller D, Khachatryan G, Khachatryan M, Khanal A, Khandaker M, Kim A, Kim W, Klein FJ, Kubarovsky V, Kuleshov SV, Kunkel MC, Lanza L, Lenisa P, Livingston K, MacGregor IJD, Marchand D, McKinnon B, Meekins DG, Meyer CA, Mineeva T, Mokeev V, Montgomery RA, Movsisyan A, Munoz Camacho C, Nadel-Turonski P, Niccolai S, Niculescu G, Osipenko M, Ostrovidov AI, Paolone M, Pappalardo LL, Paremuzyan R, Pasyuk E, Payette D, Phelps W, Pierce J, Pogorelko O, Prok Y, Protopopescu D, Raue BA, Ripani M, Riser D, Ritchie BG, Rizzo A, Rosner G, Sabatié F, Salgado C, Schumacher RA, Seely ML, Sharabian YG, Shrestha U, Skorodumina I, Sokhan D, Soto O, Sparveris N, Strakovsky II, Strauch S, Taiuti M, Tan JA, Torayev B, Tyler N, Ungaro M, Voskanyan H, Voutier E, Walford NK, Wang R, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW. First Measurements of the Double-Polarization Observables F, P, and H in ω Photoproduction off Transversely Polarized Protons in the N^{*} Resonance Region. Phys Rev Lett 2019; 122:162301. [PMID: 31075002 DOI: 10.1103/physrevlett.122.162301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 03/12/2019] [Indexed: 06/09/2023]
Abstract
First measurements of double-polarization observables in ω photoproduction off the proton are presented using transverse target polarization and data from the CEBAF Large Acceptance Spectrometer (CLAS) FROST experiment at Jefferson Lab. The beam-target asymmetry F has been measured using circularly polarized, tagged photons in the energy range 1200-2700 MeV, and the beam-target asymmetries H and P have been measured using linearly polarized, tagged photons in the energy range 1200-2000 MeV. These measurements significantly increase the database on polarization observables. The results are included in two partial-wave analyses and reveal significant contributions from several nucleon (N^{*}) resonances. In particular, contributions from new N^{*} resonances listed in the Review of Particle Properties are observed, which aid in reaching the goal of mapping out the nucleon resonance spectrum.
Collapse
Affiliation(s)
- P Roy
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Park
- Florida State University, Tallahassee, Florida 32306, USA
| | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - A V Anisovich
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - E Klempt
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - V A Nikonov
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - A V Sarantsev
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - N C Wei
- Zhengzhou University, Zhengzhou, Henan 450001, China
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - F Huang
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Nakayama
- University of Georgia, Athens, Georgia 30602, USA
| | - K P Adhikari
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | - G Angelini
- The George Washington University, Washington, DC 20052, USA
| | - H Avakian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Fairfield University, Fairfield, Connecticut 06824, USA
| | - S Boiarinov
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W J Briscoe
- The George Washington University, Washington, DC 20052, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W K Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - P Chatagnon
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Università di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - P L Cole
- Idaho State University, Pocatello, Idaho 83209, USA
- Lamar University, 4400 MLK Blvd, P.O. Box 10009, Beaumont, Texas 77710, USA
| | | | - O Cortes
- The George Washington University, Washington, DC 20052, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Università di Roma Tor Vergata, 00133 Rome, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- Ohio University, Athens, Ohio 45701, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Dugger
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - R Dupre
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - H Egiyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ehrhart
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - A El Alaoui
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Fegan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - A Fradi
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - F X Girod
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - M Guidal
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - L Guo
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - C Hanretty
- Florida State University, Tallahassee, Florida 32306, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Hattawy
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - T B Hayward
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - Y Ilieva
- The George Washington University, Washington, DC 20052, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - B S Ishkhanov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - S Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - C D Keith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Keller
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - A Kim
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - F J Klein
- Catholic University of America, Washington, D.C. 20064, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S V Kuleshov
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M C Kunkel
- Institut für Kernphysik, 52425 Jülich, Germany
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - D G Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C A Meyer
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Mineeva
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V Mokeev
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - C Munoz Camacho
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - G Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- University of South Carolina, Columbia, South Carolina 29208, USA
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | | | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Payette
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Phelps
- The George Washington University, Washington, DC 20052, USA
| | - J Pierce
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - Y Prok
- Christopher Newport University, Newport News, Virginia 23606, USA
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - B A Raue
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - D Riser
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - B G Ritchie
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Università di Roma Tor Vergata, 00133 Rome, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Sabatié
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M L Seely
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - U Shrestha
- Ohio University, Athens, Ohio 45701, USA
| | - Iu Skorodumina
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Soto
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - I I Strakovsky
- The George Washington University, Washington, DC 20052, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- Università di Genova, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - B Torayev
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N Tyler
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- University of Connecticut, Storrs, Connecticut 06269, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Voutier
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - N K Walford
- Catholic University of America, Washington, D.C. 20064, USA
| | - R Wang
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - D P Watts
- University of York, York YO10, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M H Wood
- Canisius College, Buffalo, New York 14208, USA
| | - N Zachariou
- The George Washington University, Washington, DC 20052, USA
- University of York, York YO10, United Kingdom
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| |
Collapse
|
5
|
Iqbal M, Atherton P, Macgregor C, Wieczorek A, Singer J, Walther J, Little F, Harden S, Peedell C, Cyriac A, Chowdhury S, Bayne M, Yip K, Britten A, Powell C, Brock J, Datta S, Sevitt T, Mehta A, Greystoke A. Implications for UK practice of the use of durvalumab in stage III NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz067.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Tokaca N, Gomes F, Lau S, Jackson A, Gradwell M, Gyi M, Reinius M, Valentine E, Winn E, Bhosle J, O’Brien M, Yousaf N, Blackhall F, Gilligan D, Treece S, Yip K, Geldart T, Baluch S, Gulliford T, Muthuramalingam S, Dancey G, Britten A, Brock J, Stokoe J, Jain P, Franks K, Toy E, Newsom-Davis T, Khan O, Greystoke A, Ali C, Leonard P, Summers Y, Popat S. Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30124-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Lorimer C, Walsh G, MacKinnon M, Greenwood K, Corbett A, Bedborough K, Saran F, Chalmers A, Brock J. P01.017 Geriatric Assessments in Neuro Oncology - a viable prospect. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C Lorimer
- Brighton and Sussex Medical School, Brighton, United Kingdom
| | - G Walsh
- Sussex Cancer Centre, Brighton, United Kingdom
| | - M MacKinnon
- The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - K Greenwood
- The Royal Marsden NHS Trust, Sutton, United Kingdom
| | - A Corbett
- The Royal Marsden NHS Trust, Sutton, United Kingdom
| | - K Bedborough
- The Royal Marsden NHS Trust, Sutton, United Kingdom
| | - F Saran
- The Royal Marsden NHS Trust, Sutton, United Kingdom
| | - A Chalmers
- The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - J Brock
- Sussex Cancer Centre, Brighton, United Kingdom
| |
Collapse
|
8
|
Philipps L, Brock J, Appleyard S, Doyle R. An Audit of Metastatic Cord Compression Pathways. Clin Oncol (R Coll Radiol) 2018. [DOI: 10.1016/j.clon.2018.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Waks AG, Stover DG, Barry W, Dillon D, Gjini E, Rodig SJ, Brock J, Baltay M, Savoie J, Winer EP, Krop I, Tolaney SM. Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd6-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hormone receptor-positive (HR+) tumors have fewer tumor-infiltrating lymphocytes (TILs) and lower response rates to immune checkpoint inhibitors (ICI), either as single agents or in combination with chemotherapy, than triple negative cancers. However, some HR+ cancers do respond to ICI and biomarkers that accurately reflect the immune microenvironment may help guide the use of ICI therapy. Prior evidence suggests that macrophage-related immune pathways may be relevant to the pathophysiology of HR+ BC.
Methods: HR+/HER2- patients were identified from a prospective trial of preoperative bevacizumab (preop bev) followed by bev with adriamycin/cyclophosphamide/paclitaxel dose-dense chemotherapy (chemo). Tumor samples were collected at diagnosis and surgery (pre-tx and post-tx), and PD-L1 expression (by immunohistochemistry), TILs, and Nanostring PanCancer Immune Profiling Panel were evaluated on both pre-tx and post-tx specimens. Pre-tx whole transcriptome sequencing was performed. Pathologic response at surgery was centrally assessed by Miller-Payne (MP) and residual cancer burden (RCB) scores. An immune score was calculated for each pre-tx specimen by integrating 10 published immune signatures. Immune cell subsets were inferred from bulk transcriptional data using CIBERSORT and immune cell-specific signatures from MSigDB.
Results: 55 patients who received trial therapy and had at least 1 evaluable specimen were included for analysis. Pre-tx TILs and tumor PD-L1 (tPD-L1) scores are shown in the table. 18% of pre-tx tumors had “high” (≥10%) TILs and “high” TILs were associated with significantly higher immune signature score (p=0.004). Immune score correlated highly with proportion of CIBERSORT anti-tumor M1 macrophages as well as CD8 T-cell signatures (r>0.65 and p<0.001). Higher pre-tx TILs, tPD-L1, or immune score were each significantly associated with more favorable RCB and MP in unadjusted analyses (all Spearman p<0.01 for pathologic markers; ANOVA p<0.04 for immune score). After adjustment for age and tumor grade, higher pre-tx TILs and tPD-L1 were associated with favorable RCB (p<0.01 for both), and higher pre-tx tPD-L1 correlated with favorable MP (p=0.03). Pathologic complete response occurred in 4 pts; all 4 had high pre-tx TILs, pre-tx tPD-L1, or both. Among patients with residual disease, large changes (>5%) in TILs or tPD-L1 from pre-tx to post-tx were rare: 2 pts each had large changes in TIL or tPD-L1 score (N=38/N=31 pairs, respectively).
Conclusions: High levels of tumor-lymphocyte interaction were seen in only a minority of untreated HR+ breast tumors, and did not typically change with chemo plus bev. An immune score derived from bulk RNAseq correlated with histological observations in these specimens. Nonetheless, TILs, tPD-L1, and signature-derived immune score were significantly associated with pathologic response to preop treatment in HR+ disease. Early data suggest that the role of M1 macrophages in HR+ tumors warrants further investigation.
ScoreTILs (N=50 evaluable)Tumor PD-L1 (N=51)0%0 pts (0%)28 pts (55%)>0-5% (low)19 (38%)18 (35%)>5-10% (intermediate)22 (44%)3 (6%)>10% (high)9 (18%)2 (4%)
Citation Format: Waks AG, Stover DG, Barry W, Dillon D, Gjini E, Rodig SJ, Brock J, Baltay M, Savoie J, Winer EP, Krop I, Tolaney SM. The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD6-09.
Collapse
Affiliation(s)
- AG Waks
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - DG Stover
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - W Barry
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - D Dillon
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - E Gjini
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - SJ Rodig
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J Brock
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - M Baltay
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J Savoie
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - EP Winer
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - I Krop
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - SM Tolaney
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
10
|
Overmoyer B, Regan M, Polyak K, Brock J, Van Poznak C, King T, Haddad T, Stearns V, Hwang S, Winer E. Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Stage III triple negative(TN) inflammatory breast cancer(IBC) is associated with a poor prognosis evidenced by a 15 month(mo) median disease free survival(DFS) and overall survival(OS) of 34 mo. The substantial incidence of developing distant metastasis may be due to the prevalence of cancer cells with stem cell-like features (e.g. CD44+/CD24-) in TNIBC. The transcriptional pathway JAK2/STAT3 is associated with the survival of CD44+/CD24- cells, and preclinical data demonstrates overexpression of activated STAT3(pSTAT3) in > 95% of TNIBC. Preclinical studies have shown that ruxolitinib (Incyte®Corporation), an approved JAK1/JAK2 inhibitor, suppresses pSTAT3 in IBC patient derived xenograft models, and when combined with paclitaxel, results in a synergistic reduction in tumor weight. Given the lack of a known therapeutic target in TNIBC, this preoperative proof of principle study exploits the survival mechanism of CD44+/CD24- stem cells prevalent in this disease, by combining ruxolitinib(Rux) with paclitaxel(T) followed by doxorubicin/cyclophosphamide(AC).
Methods: Up to 64 pts with newly diagnosed stage III TNIBC (cT4d, any N, M0) are eligible if they have adequate organ function and are willing to undergo 2 research biopsies(rbx) of the affected breast. Following baseline rbx, pts are randomized to a 7 day(d) run-in phase of Rux vs Rux(15 mg bid) + T(80mg/m2/wkx1). A 2nd rbx is obtained after the run-in phase. Pts randomized to RuxT continue to receive a total of Tx12 wks+Rux. Pts randomized to Rux alone, are re-randomized to receive Tx12 wks+Rux vs Tx12wks alone. Following T, all pts receive AC (A-60mg/m2,C-600mg/m2) every 14d x 4. Pts proceed to modified radical mastectomy (MRM) followed by chest wall/regional lymph nodes radiation therapy.
Correlatives: To assess the effect of JAK inhibition with Rux on pSTAT3 and STAT3 related gene expression, molecular and genomic markers (e.g. RNA-seq, ChIPseq, FISH) will be determined in each rbx and residual tumor at MRM. The relative frequency and topology of CD44+/CD24- cell population and pSTAT3 expression by IHC will also be assessed in these tumor specimens. IL-6 and CRP plasma concentrations will be measured at baseline, prior to T and AC and prior to MRM.
Statistics: The primary endpoint is change in markers of JAK/STAT inhibition. If the proportion of rbx exhibit a biologic response to Rux alone (i.e. change from pSTAT3 expression to pSTAT3 negative) is <10%, then Rux alone is minimally effective on JAK inhibition vs alternative hypothesis that Rux inhibits JAK if the proportion of biologic response is ≥33%. If ≥5/25 rbx treated with Rux alone have a biologic response then the hypothesis that biologic response is ≤10% is rejected with an error rate of 0.098 (target 0.10). If ≤4/25 rbx have a biologic response then the hypothesis that biologic response is ≥33% is rejected with an error rate of 0.05 (target 0.10). Biologic response of rbx with Rux alone will also be compared with the proportion of biologic response to RuxT (33% vs. 66% based upon presumed synergy with RuxT). Secondary endpoints are clinical: pathologic complete response in breast/lymph nodes, Residual Cancer Burden, DFS and OS. Clinical Trial Information: NCT02876302.
Citation Format: Overmoyer B, Regan M, Polyak K, Brock J, Van Poznak C, King T, Haddad T, Stearns V, Hwang S, Winer E. TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-01.
Collapse
Affiliation(s)
- B Overmoyer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - M Regan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - K Polyak
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - J Brock
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - C Van Poznak
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - T King
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - T Haddad
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - V Stearns
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - S Hwang
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Duke University Medical Center, Durham, NC; Mayo Clinic Cancer Center, Rochester, MN; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
11
|
Adhikari KP, Deur A, El Fassi L, Kang H, Kuhn SE, Ripani M, Slifer K, Zheng X, Adhikari S, Akbar Z, Amaryan MJ, Avakian H, Ball J, Balossino I, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Bosted P, Briscoe WJ, Brock J, Bültmann S, Burkert VD, Thanh Cao F, Carlin C, Carman DS, Celentano A, Charles G, Chen JP, Chetry T, Choi S, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Defurne M, Djalali C, Dodge GE, Drozdov V, Dupre R, Egiyan H, El Alaoui A, Elouadrhiri L, Eugenio P, Fedotov G, Filippi A, Ghandilyan Y, Gilfoyle GP, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Hafidi K, Hakobyan H, Hanretty C, Harrison N, Hattawy M, Heddle D, Hicks K, Holtrop M, Hyde CE, Ilieva Y, Ireland DG, Isupov EL, Jenkins D, Jo HS, Johnston SC, Joo K, Joosten S, Kabir ML, Keith CD, Keller D, Khachatryan G, Khachatryan M, Khandaker M, Kim W, Klein A, Klein FJ, Konczykowski P, Kovacs K, Kubarovsky V, Lanza L, Lenisa P, Livingston K, Long E, MacGregor IJD, Markov N, Mayer M, McKinnon B, Meekins DG, Meyer CA, Mineeva T, Mirazita M, Mokeev V, Movsisyan A, Munoz Camacho C, Nadel-Turonski P, Niculescu G, Niccolai S, Osipenko M, Ostrovidov AI, Paolone M, Pappalardo L, Paremuzyan R, Park K, Pasyuk E, Payette D, Phelps W, Phillips SK, Pierce J, Pogorelko O, Poudel J, Price JW, Prok Y, Protopopescu D, Raue BA, Rizzo A, Rosner G, Rossi P, Sabatié F, Salgado C, Schumacher RA, Sharabian YG, Shigeyuki T, Simonyan A, Skorodumina I, Smith GD, Sparveris N, Sokhan D, Stepanyan S, Strakovsky II, Strauch S, Sulkosky V, Taiuti M, Tan JA, Ungaro M, Voutier E, Wei X, Weinstein LB, Zhang J, Zhao ZW. Measurement of the Q^{2} Dependence of the Deuteron Spin Structure Function g_{1} and its Moments at Low Q^{2} with CLAS. Phys Rev Lett 2018; 120:062501. [PMID: 29481214 DOI: 10.1103/physrevlett.120.062501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 12/05/2017] [Indexed: 06/08/2023]
Abstract
We measured the g_{1} spin structure function of the deuteron at low Q^{2}, where QCD can be approximated with chiral perturbation theory (χPT). The data cover the resonance region, up to an invariant mass of W≈1.9 GeV. The generalized Gerasimov-Drell-Hearn sum, the moment Γ_{1}^{d} and the spin polarizability γ_{0}^{d} are precisely determined down to a minimum Q^{2} of 0.02 GeV^{2} for the first time, about 2.5 times lower than that of previous data. We compare them to several χPT calculations and models. These results are the first in a program of benchmark measurements of polarization observables in the χPT domain.
Collapse
Affiliation(s)
- K P Adhikari
- Old Dominion University, Norfolk, Virginia 23529, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - L El Fassi
- Old Dominion University, Norfolk, Virginia 23529, USA
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - H Kang
- Seoul National University, Seoul, Korea
| | - S E Kuhn
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - K Slifer
- University of Virginia, Charlottesville, Virginia 22901, USA
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | - Z Akbar
- Florida State University, Tallahassee, Florida 32306, USA
| | - M J Amaryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Avakian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Ball
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - I Balossino
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Fairfield University, Fairfield, Connecticut 06824, USA
| | - P Bosted
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - W J Briscoe
- The George Washington University, Washington, DC 20052, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Bültmann
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Thanh Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - G Charles
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - S Choi
- Seoul National University, Seoul, Korea
| | - G Ciullo
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - L Clark
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P L Cole
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Idaho State University, Pocatello, Idaho 83209, USA
| | | | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - M Defurne
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Djalali
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - G E Dodge
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Drozdov
- INFN, Sezione di Genova, 16146 Genova, Italy
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R Dupre
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - H Egiyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - A El Alaoui
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L Elouadrhiri
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - G Fedotov
- Ohio University, Athens, Ohio 45701, USA
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - Y Ghandilyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - M Guidal
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - N Guler
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - L Guo
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Florida International University, Miami, Florida 33199, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - H Hakobyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - C Hanretty
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Hattawy
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Heddle
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - C E Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - Y Ilieva
- The George Washington University, Washington, DC 20052, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - H S Jo
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - S C Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - K Joo
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - C D Keith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Keller
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M Khandaker
- Idaho State University, Pocatello, Idaho 83209, USA
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - A Klein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - F J Klein
- Catholic University of America, Washington, DC 20064, USA
| | - P Konczykowski
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - K Kovacs
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - E Long
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | | | - N Markov
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Mayer
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - D G Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C A Meyer
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Mineeva
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M Mirazita
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - V Mokeev
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - C Munoz Camacho
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- The George Washington University, Washington, DC 20052, USA
| | - G Niculescu
- Ohio University, Athens, Ohio 45701, USA
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - S Niccolai
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - L Pappalardo
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
- Università di Ferrara, 44121 Ferrara, Italy
| | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - K Park
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - D Payette
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Phelps
- Florida International University, Miami, Florida 33199, USA
| | - S K Phillips
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - J Pierce
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - J Poudel
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J W Price
- California State University, Dominguez Hills, Carson, California 90747, USA
| | - Y Prok
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - B A Raue
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Florida International University, Miami, Florida 33199, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P Rossi
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - F Sabatié
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Shigeyuki
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - A Simonyan
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - Iu Skorodumina
- University of South Carolina, Columbia, South Carolina 29208, USA
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - G D Smith
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - I I Strakovsky
- The George Washington University, Washington, DC 20052, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - V Sulkosky
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - M Taiuti
- INFN, Sezione di Genova, 16146 Genova, Italy
- Università di Genova, Dipartimento di Fisica, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - M Ungaro
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
| | - E Voutier
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| |
Collapse
|
12
|
Lorimer C, Hanna C, Saran F, Chalmers A, Brock J. Challenges to Treating Older Glioblastoma Patients: the Influence of Clinical and Tumour Characteristics on Survival Outcomes. Clin Oncol (R Coll Radiol) 2017; 29:739-747. [DOI: 10.1016/j.clon.2017.05.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 05/10/2017] [Accepted: 05/17/2017] [Indexed: 12/27/2022]
|
13
|
Lorimer C, Hanna C, Chalmers A, Saran F, Brock J. A multi-centre audit of treatment and outcomes for older patients with glioblastoma. Clin Oncol (R Coll Radiol) 2017. [DOI: 10.1016/j.clon.2017.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Brock J, Mugabe M, Andrici J, Rugwizangoga B, Milner D. A single FFPE lysate preparation method for use with the Xpert Breast Cancer STRAT4 provides a streamlined solution for testing in developing countries. Breast 2017. [DOI: 10.1016/s0960-9776(17)30124-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
15
|
Yang K, Downey C, Suter N, Gott L, Naughton L, Aufiero K, Day S, McGovern N, Brock J, Andreou K, Strasser J, Koprowski C, Raben A, Chen H, Mourtada F. SU-F-J-35: Moving Towards Isocentric Prone Breast Setup with Contralateral Leveling Tattoo and Couch Move Assistant (CMA). Med Phys 2016. [DOI: 10.1118/1.4955943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
16
|
Georges H, Critchley G, Lynch M, Walsh G, Creak A, Brock J. PO65TAILORING HIGH GRADE GLIOMA MANAGEMENT IN THE ELDERLY. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov284.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Brock J, Schmid A, Leszczak S, Ober I, Karrasch T, Schäffler A. Regulation of pro-inflammatory adipokines CCL2, chemerin and resistin by oral lipid ingestion in healthy probands. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-271. [PMID: 25214542 PMCID: PMC6267863 DOI: 10.1093/annonc/mdu450 10.1097/pai.0000000000000594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 08/28/2014] [Indexed: 04/29/2024] Open
Abstract
BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Collapse
Affiliation(s)
- R Salgado
- Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
| | - C Denkert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - S Demaria
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - N Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F Klauschen
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Pruneri
- European Institute of Oncology (IEO) and University of Milan, Milan, Italy
| | - S Wienert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Van den Eynden
- Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium
| | - F L Baehner
- Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA
| | - F Penault-Llorca
- Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - E A Perez
- Division of Haematology/Medical Oncology and
| | - E A Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville
| | - W F Symmans
- Department of Pathology, The UT M.D. Anderson Cancer Center, Boston
| | - A L Richardson
- Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston
| | - J Brock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA
| | | | - H Bailey
- Genomic Health, Inc., Redwood City, USA
| | - M Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - J Sparano
- Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA
| | - Z Kos
- Laboratory Medicine Program, University Health Network, University of Toronto, Toronto
| | - T Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
| | - D L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
| | - K H Allison
- Department of Pathology, Stanford University Medical Centre, Stanford
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany
| | - C Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - S Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
| | - S Adams
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| |
Collapse
|
19
|
Seder E, Biselli A, Pisano S, Niccolai S, Smith GD, Joo K, Adhikari K, Amaryan MJ, Anderson MD, Anefalos Pereira S, Avakian H, Battaglieri M, Bedlinskiy I, Bono J, Boiarinov S, Bosted P, Briscoe W, Brock J, Brooks WK, Bültmann S, Burkert VD, Carman DS, Carlin C, Celentano A, Chandavar S, Charles G, Colaneri L, Cole PL, Contalbrigo M, Crabb D, Crede V, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Deur A, Djalali C, Doughty D, Dupre R, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Fegan S, Filippi A, Fleming JA, Fradi A, Garillon B, Garçon M, Gevorgyan N, Ghandilyan Y, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Gothe RW, Griffioen KA, Guegan B, Guidal M, Guo L, Hafidi K, Hakobyan H, Hanretty C, Harrison N, Hattawy M, Hirlinger Saylor N, Holtrop M, Hughes SM, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jo HS, Joosten S, Keith CD, Keller D, Khachatryan G, Khandaker M, Kim A, Kim W, Klein A, Klein FJ, Koirala S, Kubarovsky V, Kuhn SE, Lenisa P, Livingston K, Lu HY, MacGregor IJD, Markov N, Mayer M, McKinnon B, Meekins DG, Mineeva T, Mirazita M, Mokeev V, Montgomery R, Moody CI, Moutarde H, Movsisyan A, Munoz Camacho C, Nadel-Turonski P, Niculescu I, Osipenko M, Ostrovidov AI, Paolone M, Pappalardo LL, Park K, Park S, Pasyuk E, Peng P, Phelps W, Pogorelko O, Price JW, Prok Y, Protopopescu D, Puckett AJR, Ripani M, Rizzo A, Rosner G, Rossi P, Roy P, Sabatié F, Salgado C, Schott D, Schumacher RA, Senderovich I, Simonyan A, Skorodumina I, Sokhan D, Sparveris N, Stepanyan S, Stoler P, Strakovsky II, Strauch S, Sytnik V, Taiuti M, Tang W, Tian Y, Ungaro M, Voskanyan H, Voutier E, Walford NK, Watts DP, Wei X, Weinstein LB, Wood MH, Zachariou N, Zana L, Zhang J, Zonta I. Longitudinal target-spin asymmetries for deeply virtual compton scattering. Phys Rev Lett 2015; 114:032001. [PMID: 25658994 DOI: 10.1103/physrevlett.114.032001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Indexed: 06/04/2023]
Abstract
A measurement of the electroproduction of photons off protons in the deeply inelastic regime was performed at Jefferson Lab using a nearly 6 GeV electron beam, a longitudinally polarized proton target, and the CEBAF Large Acceptance Spectrometer. Target-spin asymmetries for ep→e^{'}p^{'}γ events, which arise from the interference of the deeply virtual Compton scattering and the Bethe-Heitler processes, were extracted over the widest kinematics in Q^{2}, x_{B}, t, and ϕ, for 166 four-dimensional bins. In the framework of generalized parton distributions, at leading twist the t dependence of these asymmetries provides insight into the spatial distribution of the axial charge of the proton, which appears to be concentrated in its center. These results also bring important and necessary constraints for the existing parametrizations of chiral-even generalized parton distributions.
Collapse
Affiliation(s)
- E Seder
- University of Connecticut, Storrs, Connecticut 06269, USA and CEA, Centre de Saclay, Irfu/Service de Physique Nucléaire, 91191 Gif-sur-Yvette, France
| | - A Biselli
- Fairfield University, Fairfield, Connecticut 06824, USA
| | - S Pisano
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy and Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - S Niccolai
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - G D Smith
- University of Glasgow, Glasgow G12 8QQ, United Kingdom and Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - K Joo
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - K Adhikari
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M J Amaryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M D Anderson
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - H Avakian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow 117259, Russia
| | - J Bono
- Florida International University, Miami, Florida 33199, USA
| | - S Boiarinov
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Bosted
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - W Briscoe
- The George Washington University, Washington, D.C. 20052, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W K Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - S Bültmann
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | | | - G Charles
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - L Colaneri
- INFN, Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - P L Cole
- Idaho State University, Pocatello, Idaho 83209, USA
| | | | - D Crabb
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - V Crede
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Roma, Italy and Università di Roma Tor Vergata, 00133 Roma, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Djalali
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Doughty
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Christopher Newport University, Newport News, Virginia 23606, USA
| | - R Dupre
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France and Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - L El Fassi
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - L Elouadrhiri
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - G Fedotov
- University of South Carolina, Columbia, South Carolina 29208, USA and Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - S Fegan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom and INFN, Sezione di Genova, 16146 Genova, Italy
| | - A Filippi
- INFN, Sezione di Torino, Torino, Italy
| | - J A Fleming
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - A Fradi
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - B Garillon
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - M Garçon
- CEA, Centre de Saclay, Irfu/Service de Physique Nucléaire, 91191 Gif-sur-Yvette, France
| | - N Gevorgyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - Y Ghandilyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - K L Giovanetti
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - F X Girod
- CEA, Centre de Saclay, Irfu/Service de Physique Nucléaire, 91191 Gif-sur-Yvette, France and Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J T Goetz
- Ohio University, Athens, Ohio 45701, USA
| | - W Gohn
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - B Guegan
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - M Guidal
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - L Guo
- Florida International University, Miami, Florida 33199, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - H Hakobyan
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile and Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - C Hanretty
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - N Harrison
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Hattawy
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | | | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - S M Hughes
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - Y Ilieva
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - B S Ishkhanov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - H S Jo
- Institut de Physique Nucléaire Orsay, 91406 Orsay, France
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C D Keith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Keller
- Ohio University, Athens, Ohio 45701, USA and University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khandaker
- Idaho State University, Pocatello, Idaho 83209, USA and Norfolk State University, Norfolk, Virginia 23504, USA
| | - A Kim
- Kyungpook National University, Daegu 702-701, Republic of Korea
| | - W Kim
- Kyungpook National University, Daegu 702-701, Republic of Korea
| | - A Klein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - F J Klein
- Catholic University of America, Washington, D.C. 20064, USA
| | - S Koirala
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S E Kuhn
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Y Lu
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | - N Markov
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Mayer
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - D G Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Mineeva
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Mirazita
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - V Mokeev
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R Montgomery
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - C I Moody
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - H Moutarde
- CEA, Centre de Saclay, Irfu/Service de Physique Nucléaire, 91191 Gif-sur-Yvette, France
| | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Catholic University of America, Washington, D.C. 20064, USA
| | - I Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | | | - K Park
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and University of South Carolina, Columbia, South Carolina 29208, USA
| | - S Park
- Florida State University, Tallahassee, Florida 32306, USA
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Arizona State University, Tempe, Arizona 85287-1504, USA
| | - P Peng
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - W Phelps
- Florida International University, Miami, Florida 33199, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow 117259, Russia
| | - J W Price
- California State University, Dominguez Hills, Carson, California 90747, USA
| | - Y Prok
- Old Dominion University, Norfolk, Virginia 23529, USA
| | | | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P Rossi
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy and Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Roy
- Florida State University, Tallahassee, Florida 32306, USA
| | - F Sabatié
- CEA, Centre de Saclay, Irfu/Service de Physique Nucléaire, 91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - D Schott
- Florida International University, Miami, Florida 33199, USA and The George Washington University, Washington, D.C. 20052, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - I Senderovich
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - A Simonyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - I Skorodumina
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom and Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Stoler
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
| | - I I Strakovsky
- The George Washington University, Washington, D.C. 20052, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - V Sytnik
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M Taiuti
- INFN, Sezione di Genova, 16146 Genova, Italy and Università di Genova, 16146 Genova, Italy
| | - W Tang
- Ohio University, Athens, Ohio 45701, USA
| | - Y Tian
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- University of Connecticut, Storrs, Connecticut 06269, USA and Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Voutier
- LPSC, Université Grenoble-Alps, CNRS/IN2P3, Grenoble, France
| | - N K Walford
- Catholic University of America, Washington, D.C. 20064, USA
| | - D P Watts
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M H Wood
- University of South Carolina, Columbia, South Carolina 29208, USA and Canisius College, Buffalo, New York 14208, USA
| | - N Zachariou
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - L Zana
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA and Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - I Zonta
- INFN, Sezione di Roma Tor Vergata, 00133 Roma, Italy
| |
Collapse
|
20
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2014; 26:259-71. [PMID: 25214542 DOI: 10.1093/annonc/mdu450] [Citation(s) in RCA: 1861] [Impact Index Per Article: 186.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Collapse
Affiliation(s)
- R Salgado
- Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
| | - C Denkert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - S Demaria
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - N Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F Klauschen
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Pruneri
- European Institute of Oncology (IEO) and University of Milan, Milan, Italy
| | - S Wienert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Van den Eynden
- Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium
| | - F L Baehner
- Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA
| | - F Penault-Llorca
- Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - E A Perez
- Division of Haematology/Medical Oncology and
| | - E A Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville
| | - W F Symmans
- Department of Pathology, The UT M.D. Anderson Cancer Center, Boston
| | - A L Richardson
- Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston
| | - J Brock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA
| | | | - H Bailey
- Genomic Health, Inc., Redwood City, USA
| | - M Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - J Sparano
- Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA
| | - Z Kos
- Laboratory Medicine Program, University Health Network, University of Toronto, Toronto
| | - T Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
| | - D L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
| | - K H Allison
- Department of Pathology, Stanford University Medical Centre, Stanford
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany
| | - C Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - S Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
| | - S Adams
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| | | |
Collapse
|
21
|
He BJ, Nolte G, Nagata K, Takano D, Yamazaki T, Fujimaki Y, Maeda T, Satoh Y, Heckers S, George MS, Lopes da Silva F, de Munck JC, Van Houdt PJ, Verdaasdonk RM, Ossenblok P, Mullinger K, Bowtell R, Bagshaw AP, Keeser D, Karch S, Segmiller F, Hantschk I, Berman A, Padberg F, Pogarell O, Scharnowski F, Karch S, Hümmer S, Keeser D, Paolini M, Kirsch V, Koller G, Rauchmann B, Kupka M, Blautzik J, Pogarell O, Razavi N, Jann K, Koenig T, Kottlow M, Hauf M, Strik W, Dierks T, Gotman J, Vulliemoz S, Lu Y, Zhang H, Yang L, Worrell G, He B, Gruber O, Piguet C, Hubl D, Homan P, Kindler J, Dierks T, Kim K, Steinhoff U, Wakai R, Koenig T, Kottlow M, Melie-García L, Mucci A, Volpe U, Prinster A, Salvatore M, Galderisi S, Linden DEJ, Brandeis D, Schroeder CE, Kayser C, Panzeri S, Kleinschmidt A, Ritter P, Walther S, Haueisen J, Lau S, Flemming L, Sonntag H, Maess B, Knösche TR, Lanfer B, Dannhauer M, Wolters CH, Stenroos M, Haueisen J, Wolters C, Aydin U, Lanfer B, Lew S, Lucka F, Ruthotto L, Vorwerk J, Wagner S, Ramon C, Guan C, Ang KK, Chua SG, Kuah WK, Phua KS, Chew E, Zhou H, Chuang KH, Ang BT, Wang C, Zhang H, Yang H, Chin ZY, Yu H, Pan Y, Collins L, Mainsah B, Colwell K, Morton K, Ryan D, Sellers E, Caves K, Throckmorton S, Kübler A, Holz EM, Zickler C, Sellers E, Ryan D, Brown K, Colwell K, Mainsah B, Caves K, Throckmorton S, Collins L, Wennberg R, Ahlfors SP, Grova C, Chowdhury R, Hedrich T, Heers M, Zelmann R, Hall JA, Lina JM, Kobayashi E, Oostendorp T, van Dam P, Oosterhof P, Linnenbank A, Coronel R, van Dessel P, de Bakker J, Rossion B, Jacques C, Witthoft N, Weiner KS, Foster BL, Miller KJ, Hermes D, Parvizi J, Grill-Spector K, Recanzone GH, Murray MM, Haynes JD, Richiardi J, Greicius M, De Lucia M, Müller KR, Formisano E, Smieskova R, Schmidt A, Bendfeldt K, Walter A, Riecher-Rössler A, Borgwardt S, Fusar-Poli P, Eliez S, Schmidt A, Sekihara K, Nagarajan SS, Schoffelen JM, Guggisberg AG, Nolte G, Balazs S, Kermanshahi K, Kiesenhofer W, Binder H, Rattay F, Antal A, Chaieb L, Paulus W, Bodis-Wollner I, Maurer K, Fein G, Camchong J, Johnstone J, Cardenas-Nicolson V, Fiederer LDJ, Lucka F, Yang S, Vorwerk J, Dümpelmann M, Cosandier-Rimélé D, Schulze-Bonhage A, Aertsen A, Speck O, Wolters CH, Ball T, Fuchs M, Wagner M, Kastner J, Tech R, Dinh C, Haueisen J, Baumgarten D, Hämäläinen MS, Lau S, Vogrin SJ, D'Souza W, Haueisen J, Cook MJ, Custo A, Van De Ville D, Vulliemoz S, Grouiller F, Michel CM, Malmivuo J, Aydin U, Vorwerk J, Küpper P, Heers M, Kugel H, Wellmer J, Kellinghaus C, Scherg M, Rampp S, Wolters C, Storti SF, Boscolo Galazzo I, Del Felice A, Pizzini FB, Arcaro C, Formaggio E, Mai R, Manganotti P, Koessler L, Vignal J, Cecchin T, Colnat-Coulbois S, Vespignani H, Ramantani G, Maillard L, Rektor I, Kuba R, Brázdil M, Chrastina J, Rektorova I, van Mierlo P, Carrette E, Strobbe G, Montes-Restrepo V, Vonck K, Vandenberghe S, Ahmed B, Brodely C, Carlson C, Kuzniecky R, Devinsky O, French J, Thesen T, Bénis D, David O, Lachaux JP, Seigneuret E, Krack P, Fraix V, Chabardès S, Bastin J, Jann K, Gee D, Kilroy E, Cannon T, Wang DJ, Hale JR, Mayhew SD, Przezdzik I, Arvanitis TN, Bagshaw AP, Plomp G, Quairiaux C, Astolfi L, Michel CM, Mayhew SD, Mullinger KJ, Bagshaw AP, Bowtell R, Francis ST, Schouten AC, Campfens SF, van der Kooij H, Koles Z, Lind J, Flor-Henry P, Wirth M, Haase CM, Villeneuve S, Vogel J, Jagust WJ, Kambeitz-Ilankovic L, Simon-Vermot L, Gesierich B, Duering M, Ewers M, Rektorova I, Krajcovicova L, Marecek R, Mikl M, Bracht T, Horn H, Strik W, Federspiel A, Schnell S, Höfle O, Stegmayer K, Wiest R, Dierks T, Müller TJ, Walther S, Surmeli T, Ertem A, Eralp E, Kos IH, Skrandies W, Flüggen S, Klein A, Britz J, Díaz Hernàndez L, Ro T, Michel CM, Lenartowicz A, Lau E, Rodriguez C, Cohen MS, Loo SK, Di Lorenzo G, Pagani M, Monaco L, Daverio A, Giannoudas I, La Porta P, Verardo AR, Niolu C, Fernandez I, Siracusano A, Flor-Henry P, Lind J, Koles Z, Bollmann S, Ghisleni C, O'Gorman R, Poil SS, Klaver P, Michels L, Martin E, Ball J, Eich-Höchli D, Brandeis D, Salisbury DF, Murphy TK, Butera CD, Mathalon DH, Fryer SL, Kiehl KA, Calhoun VC, Pearlson GD, Roach BJ, Ford JM, McGlashan TH, Woods SW, Volpe U, Merlotti E, Vignapiano A, Montefusco V, Plescia GM, Gallo O, Romano P, Mucci A, Galderisi S, Mingoia G, Langbein K, Dietzek M, Wagner G, Smesny, Scherpiet S, Maitra R, Gaser C, Sauer H, Nenadic I, Gonzalez Andino S, Grave de Peralta Menendez R, Grave de Peralta Menendez R, Sanchez Vives M, Rebollo B, Gonzalez Andino S, Frølich L, Andersen TS, Mørup M, Belfiore P, Gargiulo P, Ramon C, Vanhatalo S, Cho JH, Vorwerk J, Wolters CH, Knösche TR, Watanabe T, Kawabata Y, Ukegawa D, Kawabata S, Adachi Y, Sekihara K, Sekihara K, Nagarajan SS, Wagner S, Aydin U, Vorwerk J, Herrmann C, Burger M, Wolters C, Lucka F, Aydin U, Vorwerk J, Burger M, Wolters C, Bauer M, Trahms L, Sander T, Faber PL, Lehmann D, Gianotti LRR, Pascual-Marqui RD, Milz P, Kochi K, Kaneko S, Yamashita S, Yana K, Kalogianni K, Vardy AN, Schouten AC, van der Helm FCT, Sorrentino A, Luria G, Aramini R, Hunold A, Funke M, Eichardt R, Haueisen J, Gómez-Aguilar F, Vázquez-Olvera S, Cordova-Fraga T, Castro-López J, Hernández-Gonzalez MA, Solorio-Meza S, Sosa-Aquino M, Bernal-Alvarado JJ, Vargas-Luna M, Vorwerk J, Magyari L, Ludewig J, Oostenveld R, Wolters CH, Vorwerk J, Engwer C, Ludewig J, Wolters C, Sato K, Nishibe T, Furuya M, Yamashiro K, Yana K, Ono T, Puthanmadam Subramaniyam N, Hyttinen J, Lau S, Güllmar D, Flemming L, Haueisen J, Sonntag H, Vorwerk J, Wolters CH, Grasedyck L, Haueisen J, Maeß B, Freitag S, Graichen U, Fiedler P, Strohmeier D, Haueisen J, Stenroos M, Hauk O, Grigutsch M, Felber M, Maess B, Herrmann B, Strobbe G, van Mierlo P, Vandenberghe S, Strobbe G, Cárdenas-Peña D, Montes-Restrepo V, van Mierlo P, Castellanos-Dominguez G, Vandenberghe S, Lanfer B, Paul-Jordanov I, Scherg M, Wolters CH, Ito Y, Sato D, Kamada K, Kobayashi T, Dalal SS, Rampp S, Willomitzer F, Arold O, Fouladi-Movahed S, Häusler G, Stefan H, Ettl S, Zhang S, Zhang Y, Li H, Kong X, Montes-Restrepo V, Strobbe G, van Mierlo P, Vandenberghe S, Wong DDE, Bidet-Caulet A, Knight RT, Crone NE, Dalal SS, Birot G, Spinelli L, Vulliémoz S, Seeck M, Michel CM, Emory H, Wells C, Mizrahi N, Vogrin SJ, Lau S, Cook MJ, Karahanoglu FI, Grouiller F, Caballero-Gaudes C, Seeck M, Vulliemoz S, Van De Ville D, Spinelli L, Megevand P, Genetti M, Schaller K, Michel C, Vulliemoz S, Seeck M, Genetti M, Tyrand R, Grouiller F, Vulliemoz S, Spinelli L, Seeck M, Schaller K, Michel CM, Grouiller F, Heinzer S, Delattre B, Lazeyras F, Spinelli L, Pittau F, Seeck M, Ratib O, Vargas M, Garibotto V, Vulliemoz S, Vogrin SJ, Bailey CA, Kean M, Warren AE, Davidson A, Seal M, Harvey AS, Archer JS, Papadopoulou M, Leite M, van Mierlo P, Vonck K, Boon P, Friston K, Marinazzo D, Ramon C, Holmes M, Koessler L, Rikir E, Gavaret M, Bartolomei F, Vignal JP, Vespignani H, Maillard L, Centeno M, Perani S, Pier K, Lemieux L, Clayden J, Clark C, Pressler R, Cross H, Carmichael DW, Spring A, Bessemer R, Pittman D, Aghakhani Y, Federico P, Pittau F, Grouiller F, Vulliémoz S, Gotman J, Badier JM, Bénar CG, Bartolomei F, Cruto C, Chauvel P, Gavaret M, Brodbeck V, van Leeuwen T, Tagliazzuchi E, Melloni L, Laufs H, Griskova-Bulanova I, Dapsys K, Klein C, Hänggi J, Jäncke L, Ehinger BV, Fischer P, Gert AL, Kaufhold L, Weber F, Marchante Fernandez M, Pipa G, König P, Sekihara K, Hiyama E, Koga R, Iannilli E, Michel CM, Bartmuss AL, Gupta N, Hummel T, Boecker R, Holz N, Buchmann AF, Blomeyer D, Plichta MM, Wolf I, Baumeister S, Meyer-Lindenberg A, Banaschewski T, Brandeis D, Laucht M, Natahara S, Ueno M, Kobayashi T, Kottlow M, Bänninger A, Koenig T, Schwab S, Koenig T, Federspiel A, Dierks T, Jann K, Natsukawa H, Kobayashi T, Tüshaus L, Koenig T, Kottlow M, Achermann P, Wilson RS, Mayhew SD, Assecondi S, Arvanitis TN, Bagshaw AP, Darque A, Rihs TA, Grouiller F, Lazeyras F, Ha-Vinh Leuchter R, Caballero C, Michel CM, Hüppi PS, Hauser TU, Hunt LT, Iannaccone R, Stämpfli P, Brandeis D, Dolan RJ, Walitza S, Brem S, Graichen U, Eichardt R, Fiedler P, Strohmeier D, Freitag S, Zanow F, Haueisen J, Lordier L, Grouiller F, Van de Ville D, Sancho Rossignol A, Cordero I, Lazeyras F, Ansermet F, Hüppi P, Schläpfer A, Rubia K, Brandeis D, Di Lorenzo G, Pagani M, Monaco L, Daverio A, Giannoudas I, Verardo AR, La Porta P, Niolu C, Fernandez I, Siracusano A, Tamura K, Karube C, Mizuba T, Matsufuji M, Takashima S, Iramina K, Assecondi S, Ostwald D, Bagshaw AP, Marecek R, Brazdil M, Lamos M, Slavícek T, Marecek R, Jan J, Meier NM, Perrig W, Koenig T, Minami T, Noritake Y, Nakauchi S, Azuma K, Minami T, Nakauchi S, Rodriguez C, Lenartowicz A, Cohen MS, Rodriguez C, Lenartowicz A, Cohen MS, Iramina K, Kinoshita H, Tamura K, Karube C, Kaneko M, Ide J, Noguchi Y, Cohen MS, Douglas PK, Rodriguez CM, Xia HJ, Zimmerman EM, Konopka CJ, Epstein PS, Konopka LM, Giezendanner S, Fisler M, Soravia L, Andreotti J, Wiest R, Dierks T, Federspiel A, Razavi N, Federspiel A, Dierks T, Hauf M, Jann K, Kamada K, Sato D, Ito Y, Okano K, Mizutani N, Kobayashi T, Thelen A, Murray M, Pastena L, Formaggio E, Storti SF, Faralli F, Melucci M, Gagliardi R, Ricciardi L, Ruffino G, Coito A, Macku P, Tyrand R, Astolfi L, He B, Wiest R, Seeck M, Michel C, Plomp G, Vulliemoz S, Fischmeister FPS, Glaser J, Schöpf V, Bauer H, Beisteiner R, Deligianni F, Centeno M, Carmichael DW, Clayden J, Mingoia G, Langbein K, Dietzek M, Wagner G, Smesny S, Scherpiet S, Maitra R, Gaser C, Sauer H, Nenadic I, Dürschmid S, Zaehle T, Pannek H, Chang HF, Voges J, Rieger J, Knight RT, Heinze HJ, Hinrichs H, Tsatsishvili V, Cong F, Puoliväli T, Alluri V, Toiviainen P, Nandi AK, Brattico E, Ristaniemi T, Grieder M, Crinelli RM, Jann K, Federspiel A, Wirth M, Koenig T, Stein M, Wahlund LO, Dierks T, Atsumori H, Yamaguchi R, Okano Y, Sato H, Funane T, Sakamoto K, Kiguchi M, Tränkner A, Schindler S, Schmidt F, Strauß M, Trampel R, Hegerl U, Turner R, Geyer S, Schönknecht P, Kebets V, van Assche M, Goldstein R, van der Meulen M, Vuilleumier P, Richiardi J, Van De Ville D, Assal F, Wozniak-Kwasniewska A, Szekely D, Harquel S, Bougerol T, David O, Bracht T, Jones DK, Horn H, Müller TJ, Walther S, Sos P, Klirova M, Novak T, Brunovsky M, Horacek J, Bares M, Hoschl C C, Fellhauer I, Zöllner FG, Schröder J, Kong L, Essig M, Schad LR, Arrubla J, Neuner I, Hahn D, Boers F, Shah NJ, Neuner I, Arrubla J, Hahn D, Boers F, Jon Shah N, Suriya Prakash M, Sharma R, Kawaguchi H, Kobayashi T, Fiedler P, Griebel S, Biller S, Fonseca C, Vaz F, Zentner L, Zanow F, Haueisen J, Rochas V, Rihs T, Thut G, Rosenberg N, Landis T, Michel C, Moliadze V, Schmanke T, Lyzhko E, Bassüner S, Freitag C, Siniatchkin M, Thézé R, Guggisberg AG, Nahum L, Schnider A, Meier L, Friedrich H, Jann K, Landis B, Wiest R, Federspiel A, Strik W, Dierks T, Witte M, Kober SE, Neuper C, Wood G, König R, Matysiak A, Kordecki W, Sieluzycki C, Zacharias N, Heil P, Wyss C, Boers F, Arrubla J, Dammers J, Kawohl W, Neuner I, Shah NJ, Braboszcz C, Cahn RB, Levy J, Fernandez M, Delorme A, Rosas-Martinez L, Milne E, Zheng Y, Urakami Y, Kawamura K, Washizawa Y, Hiyoshi K, Cichocki A, Giroud N, Dellwo V, Meyer M, Rufener KS, Liem F, Dellwo V, Meyer M, Jones-Rounds JD, Raizada R, Staljanssens W, Strobbe G, van Mierlo P, Van Holen R, Vandenberghe S, Pefkou M, Becker R, Michel C, Hervais-Adelman A, He W, Brock J, Johnson B, Ohla K, Hitz K, Heekeren K, Obermann C, Huber T, Juckel G, Kawohl W, Gabriel D, Comte A, Henriques J, Magnin E, Grigoryeva L, Ortega JP, Haffen E, Moulin T, Pazart L, Aubry R, Kukleta M, Baris Turak B, Louvel J, Crespo-Garcia M, Cantero JL, Atienza M, Connell S, Kilborn K, Damborská A, Brázdil M, Rektor I, Kukleta M, Koberda JL, Bienkiewicz A, Koberda I, Koberda P, Moses A, Tomescu M, Rihs T, Britz J, Custo A, Grouiller F, Schneider M, Debbané M, Eliez S, Michel C, Wang GY, Kydd R, Wouldes TA, Jensen M, Russell BR, Dissanayaka N, Au T, Angwin A, O'Sullivan J, Byrne G, Silburn P, Marsh R, Mellic G, Copland D, Bänninger A, Kottlow M, Díaz Hernàndez L, Koenig T, Díaz Hernàndez L, Bänninger A, Koenig T, Hauser TU, Iannaccone R, Mathys C, Ball J, Drechsler R, Brandeis D, Walitza S, Brem S, Boeijinga PH, Pang EW, Valica T, Macdonald MJ, Oh A, Lerch JP, Anagnostou E, Di Lorenzo G, Pagani M, Monaco L, Daverio A, Verardo AR, Giannoudas I, La Porta P, Niolu C, Fernandez I, Siracusano A, Shimada T, Matsuda Y, Monkawa A, Monkawa T, Hashimoto R, Watanabe K, Kawasaki Y, Matsuda Y, Shimada T, Monkawa T, Monkawa A, Watanabe K, Kawasaki Y, Stegmayer K, Horn H, Federspiel A, Razavi N, Bracht T, Laimböck K, Strik W, Dierks T, Wiest R, Müller TJ, Walther S, Koorenhof LJ, Swithenby SJ, Martins-Mourao A, Rihs TA, Tomescu M, Song KW, Custo A, Knebel JF, Murray M, Eliez S, Michel CM, Volpe U, Merlotti E, Vignapiano A, Montefusco V, Plescia GM, Gallo O, Romano P, Mucci A, Galderisi S, Laimboeck K, Jann K, Walther S, Federspiel A, Wiest R, Strik W, Horn H. Abstracts of Presentations at the International Conference on Basic and Clinical Multimodal Imaging (BaCI), a Joint Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), the International Society for Functional Source Imaging (ISFSI), the International Society for Bioelectromagnetism (ISBEM), the International Society for Brain Electromagnetic Topography (ISBET), and the EEG and Clinical Neuroscience Society (ECNS), in Geneva, Switzerland, September 5-8, 2013. Clin EEG Neurosci 2013; 44:1550059413507209. [PMID: 24368763 DOI: 10.1177/1550059413507209] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- B J He
- National Institutes of Health, Bethesda, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Iannalfi A, Fragkandrea I, Brock J, Saran F. Radiotherapy in Craniopharyngiomas. Clin Oncol (R Coll Radiol) 2013; 25:654-67. [DOI: 10.1016/j.clon.2013.07.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 04/29/2013] [Accepted: 05/02/2013] [Indexed: 11/15/2022]
|
23
|
Fulmer AM, Walls JT, Dutta B, Parkunan V, Brock J, Kemerait RC. First Report of Target Spot Caused by Corynespora cassiicola on Cotton in Georgia. Plant Dis 2012; 96:1066. [PMID: 30727240 DOI: 10.1094/pdis-01-12-0035-pdn] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
In 2005, crop consultants in southwestern Georgia reported an unusual occurrence of leaf spot in cotton (Gossypium hirsutum L.). Initial symptoms first developed as brick red dots that led to the formation of irregular to circular lesions with tan-to-light brown centers. Lesions further enlarged and often demonstrated a targetlike appearance formed from concentric rings within the spot. Observations included estimates of premature defoliation up to 70%, abundant characteristic spots on the leaves and bracts, and losses of several hundred kg of lint/ha. When symptomatic leaves were submitted to the University of Georgia Tifton Plant Disease Clinic in Tifton, GA, for identification in 2008, the causal agent was tentatively diagnosed as Corynespora cassiicola (Berk. & M.A. Curtis) C.T. Wei on the basis of similar symptoms and signs previously reported on cotton (3). In September 2011, symptomatic leaves were obtained from diseased cotton within a field (var. DP 1048B2RF) near Attapulgus, GA. Symptomatic tissue from diseased leaves was surface disinfested in 0.5% sodium hypochlorite for 1 min and plated on potato dextrose agar (PDA). Ten isolates were incubated at 21.1°C for 2 weeks with a 12/12 h light/dark cycle using fluorescent light located approximately 70 cm above the cultures. After 1 week, two isolates were transferred to quarter strength PDA for enhanced sporulation and were grown under the same conditions. Conidiophores from the isolated fungus were simple, erect, intermittently branching and septate, and gave rise to single, subhyaline conidia. Conidia had 4 to 17 pseudosepta and were 50 to 197 μm long and 7 to 16 μm wide, straight to curved, and obclavate to cylindrical. Pathogenicity tests were conducted by spraying 10 cotton seedlings (DP 555BR and DP 1048B2RF, two to four true leaf stage) until runoff with a blended suspension from a 2-week-old pure culture of the fungus diluted with 100 mL of sterile water. Five plants were sprayed with sterile water as noninoculated controls. Cotton seedlings were then incubated in a moist chamber at 21.1°C for 48 h. Within 1 week, all inoculated plants showed symptoms similar to those of diseased field plants. Symptoms were not observed on noninoculated control plants. The fungus was reisolated five times from symptomatic leaves and grown in pure culture. Conidia and conidiophores were identical to the morphology of the original isolates, and were similar to descriptions of C. cassiicola (2). To confirm the identity of the pathogen, DNA was extracted from a week-old culture and amplified with specific primers for loci "ga4" and "rDNA ITS" (1). DNA sequences obtained with the Applied Biosystems 3730xl 96-capillary DNA Analyzer showed 99% identity to C. cassiicola from BLAST analysis in GenBank. The resulting sequence was deposited into GenBank (Accession No. JQ717069). To our knowledge, this is the first report of this pathogen in Georgia. Given the increasing prevalence of this disease in southwestern Georgia, its confirmation is a significant step toward management recommendations for growers. Because foliar diseases caused by C. cassiicola are commonly referred to as "target spot" in other crops (e.g., soybeans), it is proposed that Corynespora leaf spot of cotton be known as "target spot of cotton." References: (1) L. J. Dixon et al. Phytopathology 99:1015, 2009. (2) M. B. Ellis and P. Holliday. CMI Description of Pathogenic Fungi and Bacteria, 303, 1971. (3) J. P. Jones. Phytopathology 51:305, 1961.
Collapse
Affiliation(s)
- A M Fulmer
- Department of Plant Pathology, University of Georgia, Coastal Plain Experiment Station, Tifton, GA 31793
| | - J T Walls
- Department of Plant Pathology, University of Georgia, Coastal Plain Experiment Station, Tifton, GA 31793
| | - B Dutta
- Department of Plant Pathology, University of Georgia, Coastal Plain Experiment Station, Tifton, GA 31793
| | - V Parkunan
- Department of Plant Pathology, University of Georgia, Coastal Plain Experiment Station, Tifton, GA 31793
| | - J Brock
- Department of Plant Pathology, University of Georgia, Coastal Plain Experiment Station, Tifton, GA 31793
| | - R C Kemerait
- Department of Plant Pathology, University of Georgia, Coastal Plain Experiment Station, Tifton, GA 31793
| |
Collapse
|
24
|
Brock J, Bedford J, Partridge M, McDonald F, Ashley S, McNair HA, Brada M. Optimising stereotactic body radiotherapy for non-small cell lung cancer with volumetric intensity-modulated arc therapy--a planning study. Clin Oncol (R Coll Radiol) 2012; 24:68-75. [PMID: 21396808 DOI: 10.1016/j.clon.2011.02.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 12/13/2010] [Accepted: 12/14/2010] [Indexed: 12/25/2022]
Abstract
AIMS The potential advantages of stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer (NSCLC) over conventional fractionated radiotherapy include a higher biological effective dose, a reduction in accelerated repopulation, greater patient convenience and reduced demand on radiotherapy resources. Before introducing SBRT in our department, a review of planning and delivery was undertaken, starting with an assessment of optimum beam number and arrangement. MATERIALS AND METHODS Radiotherapy planning computed tomography scans for five patients previously treated for T1 peripheral NSCLC were selected. In each the contoured tumour had planning target volume (PTV) margins of 1cm in all directions. Forward-planned three-field coplanar and non-coplanar plans and a seven-field coplanar plan were produced and optimised. In-house inverse-planning software (AutoBeam) was used to generate three-, five-, seven- and nine-field coplanar and non-coplanar plans and two volumetric intensity-modulated arc therapy (VMAT) plans. The resulting V(20), V(11), PTV(90), PTV(95) and mean lung dose were compared. RESULTS Analysis of variance showed non-coplanar plans to have lower V(11) and higher PTV(90) and PTV(95) than coplanar plans. VMAT showed equivalent V(20) and target coverage when compared with the best non-coplanar plans, but with a faster delivery time (2min 8s versus 12min 40s). CONCLUSIONS Inverse-planned five-field non-coplanar plans and VMAT improve target coverage while minimising the higher dose to normal lung tissue for SBRT of NSCLC compared with coplanar beam arrangements. VMAT is preferable because of significantly shorter treatment delivery times.
Collapse
Affiliation(s)
- J Brock
- The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
| | | | | | | | | | | | | |
Collapse
|
25
|
Wilson CE, Brock J, Palermo R. Attention to social stimuli and facial identity recognition skills in autism spectrum disorder. J Intellect Disabil Res 2010; 54:1104-1115. [PMID: 20977517 DOI: 10.1111/j.1365-2788.2010.01340.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND Previous research suggests that individuals with autism spectrum disorder (ASD) have a reduced preference for viewing social stimuli in the environment and impaired facial identity recognition. METHODS Here, we directly tested a link between these two phenomena in 13 ASD children and 13 age-matched typically developing (TD) controls. Eye movements were recorded while participants passively viewed visual scenes containing people and objects. Participants also completed independent matching tasks for faces and objects. RESULTS AND CONCLUSIONS Behavioural data showed that participants with ASD were impaired on both face- and object-matching tasks relative to TD controls. Eye-tracking data revealed that both groups showed a strong bias to orient towards people. TD children spent proportionally more time looking at people than objects; however, there was no difference in viewing times between people and objects in the ASD group. In the ASD group, an individual's preference for looking first at the people in scenes was associated with level of face recognition ability. Further research is required to determine whether a causal relationship exists between these factors.
Collapse
Affiliation(s)
- C E Wilson
- Macquarie Centre for Cognitive Science, Macquarie University, Sydney, Australia.
| | | | | |
Collapse
|
26
|
McDonald F, McNair H, Brock J, Bedford J, Hansen V, Locke I, Brada M. VISUAL: Clinical implementation of volumetric modulated arc therapy (VMAT) image-guided stereotactic radiotherapy using active breathing control (ABC) for small volume lung tumours. Lung Cancer 2010. [DOI: 10.1016/s0169-5002(10)70089-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Bulman M, Brock J, Brownsell E, Schwarz M. Identification of large deletions and duplications in the CFTR gene using Multiple Ligation-dependent Probe Assay (MLPA), including one novel duplication and two novel deletions. J Cyst Fibros 2009. [DOI: 10.1016/s1569-1993(09)60020-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Akita G, Nakamura R, Miyamoto G, Brock J, Fujimoto M, Oishi F, Onizuka D, Sumikawa D. EPIZOOTIOLOGIC STUDY OF MID-CYCLE DISEASE OF LARVAL Macrobrachium rosenbergii. ACTA ACUST UNITED AC 2009. [DOI: 10.1111/j.1749-7345.1981.tb00297.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Sgroi D, Goss P, Steffel L, Lester S, Brock J, Hameed O, Hattab E, Ma X, Erlander M. Comparison of risk stratification by OncotypeDX versus HOXB13/IL17BR index and molecular grade index in 166 estrogen receptor positive patients from multiple institutions. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1072
Background
 We have previously reported two complementary prognostic markers in breast cancer for predicting risk of recurrence (Ma et al, Clin Cancer Res, 2008): a molecular grade index (MGI) that recapitulates grade 1 and 3 tumors and stratifies grade 2 tumors, and a gene expression index (HOXB13/IL17BR or H/I) that predicts clinical outcome in estrogen receptor positive (ER+) patients and endocrine benefit (Jerevell et al, Breast Cancer Res Treat, 2007). In combination, MGI and H/I define three risk groups: Low risk (low MGI), intermediate risk (low H/I, high MGI) and high risk (high H/I, high MGI). We conducted a study to compare risk stratification by MGI and H/I within samples for which a previous recurrence score (RS) by Oncotype Dx was reported.
 Materials and Methods
 RNA was extracted from formalin-fixed paraffin-embedded sections from all obtainable samples of patients (pts) from five institutions in which a RS was reported MGH, 77pts; Brigham, 48pts; IU, 19pts; UAB, 13pts; Scripps, 9pts. Real-time RT-PCR assays for MGI and H/I were completed and binary results of low and high for both were determined using pre-defined cutpoints. Risk stratification via MGI + H/I for each sample was compared to previously reported RS's (low, intermediate or high).
 Results
 For the 166 pts, 48% had a low, 45% intermediate and 7% high RS's. Overall, risk stratifications by RS versus MGI + H/I were significantly correlated (p < 0.001) with 81% of patients with low RS also having low risk (low MGI). Risk stratification by H/I + MGI reduced intermediate risk via RS by 2.5-fold (45% versus 18%).
 
 Discussion
 In ER+ pts, MGI + H/I produces a significantly smaller group of patients with intermediate risk by re-stratifying a large number of patients with intermediate RS into low and high risk groups. Risk stratification by H/I + MGI in ER+ pts is by measurement of two discrete parameters: endocrine responsiveness (H/I) and proliferative status (MGI). This may allow for more informed treatment decisions by the treating oncologist. Further studies with clinical outcome are required to establish the clinical significance of these different risk stratification methods.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1072.
Collapse
Affiliation(s)
- D Sgroi
- 1 Molecular Pathology, MGH Cancer Center, Mass. Gen. Hospital, Harvard Med. School, Boston, MA
| | - P Goss
- 1 Molecular Pathology, MGH Cancer Center, Mass. Gen. Hospital, Harvard Med. School, Boston, MA
| | - L Steffel
- 1 Molecular Pathology, MGH Cancer Center, Mass. Gen. Hospital, Harvard Med. School, Boston, MA
| | - S Lester
- 2 Pathology, Brigham and Women's Hospital, Boston, MA
| | - J Brock
- 2 Pathology, Brigham and Women's Hospital, Boston, MA
| | - O Hameed
- 3 Pathology, University of Alabama, Birmingham, Birmingham, AL
| | - E Hattab
- 4 Pathology & Laboratory Medicine, University of Indiana, Indianapolis, IN
| | - X Ma
- 5 R&D, AviaraDx, San Diego, CA
| | | |
Collapse
|
30
|
Brock J, Ashley S, Bedford J, Nioutsikou E, Partridge M, Brada M. Review of Hypofractionated Small Volume Radiotherapy for Early-stage Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol) 2008; 20:666-76. [DOI: 10.1016/j.clon.2008.06.005] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2008] [Revised: 05/12/2008] [Accepted: 06/12/2008] [Indexed: 12/25/2022]
|
31
|
Colgan R, McClelland J, McQuaid D, Evans PM, Hawkes D, Brock J, Landau D, Webb S. Planning lung radiotherapy using 4D CT data and a motion model. Phys Med Biol 2008; 53:5815-30. [DOI: 10.1088/0031-9155/53/20/017] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
32
|
|
33
|
McDonald A, Brock J, Hedner U, Ezban M, Roberts H, Monroe D, Hoffman M. RESTORING INITIAL THROMBIN GENERATION DOES NOT NORMALIZE CUTANEOUS WOUND HEALING IN HEMOPHILIA B. J Thromb Haemost 2007. [DOI: 10.1111/j.1538-7836.2007.tb01902.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Hartman J, Small W, Wilson TS, Brock J, Buckley PR, Benett WJ, Loge JM, Maitland DJ. Embolectomy in a rabbit acute arterial occlusion model using a novel electromechanical extraction device. AJNR Am J Neuroradiol 2007; 28:872-4. [PMID: 17494660 PMCID: PMC8134337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
A prototype endovascular electromechanical clot-extraction device was fabricated using a combination of shape memory polymer and shape memory nickel-titanium alloy (nitinol). Five embolic vascular occlusions were created in 4 rabbits by injecting thermally coagulated blood through a 4F catheter in the common carotid artery. Angiography immediately after clot injection showed complete or partial occlusion of the common carotid artery. Posttreatment angiography showed complete (2/5), partial (2/5), or no (1/5) restoration of blood flow.
Collapse
Affiliation(s)
- J Hartman
- Department of Radiology, University of California-Davis School of Medicine, Sacramento, CA, USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Parsons GH, Bommer WJ, Siefkin AD, Brock J, Lantz BMT. Drainage routes of bronchial blood flow in anaesthetized sheep. Pulm Pharmacol Ther 2006; 20:109-11. [PMID: 16434223 DOI: 10.1016/j.pupt.2005.12.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2005] [Accepted: 12/02/2005] [Indexed: 10/25/2022]
Abstract
The systemic circulation to the lung supplies the trachea and airway walls and may be important in the pathophysiology of asthma and pulmonary oedema. An understanding of the venous drainage pathways of this bronchial blood flow may be therapeutically important. The purpose of this study was to understand the normal drainage pathways in sheep. In seven anaesthetized, ventilated sheep we injected echo contrast agents into a systemic vein or into the bronchial artery while performing echocardiography to determine whether the drainage could be observed to the right heart and/or to the left heart. During transoesophageal echo (n=5) or heart surface echo (n=2), cephalic vein injection of <8 microm diameter gelatin microballoons promptly opacified the right but never the left-sided circulation. Air in agitated saline in the seven animals showed the same result. By contrast, injection into the bronchial artery promptly opacified the left atrium, left ventricle, and aorta but not the right-sided circulation in all seven microballoon injections and all but one of the air in agitated saline injections. The failure of the echo agents to pass through the pulmonary circulation may be related to sheep pulmonary intravascular macrophages or the surface forces on air bubbles of small size promoting collapse. The main conclusion is that there are bronchopulmonary anastomoses that connect the bronchial circulation to the pulmonary venous circulation connecting distal to the pulmonary capillaries. Any bronchial venous drainage to the right-sided circulation must have been below the detection level of the instruments and would in any case appear to be much less that the post-pulmonary capillary anastomoses noted. Pulmonary venous hypertension would be expected to have a direct effect on the bronchial circulation.
Collapse
Affiliation(s)
- G H Parsons
- Department of Medicine, University of California, Davis Heath System, Sacramento, CA 95817, USA.
| | | | | | | | | |
Collapse
|
36
|
Sconyers L, Kemerait R, Brock J, Phillips D. Asian Soybean Rust Development in 2005: A Perspective from the Southeastern United States. ACTA ACUST UNITED AC 2006. [DOI: 10.1094/apsnetfeatures-2006-0106] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Affiliation(s)
- J Brock
- Le Vieux Moulin, Rue A L'Or, St Saviours, GY7 9XS, Guernsey, UK.
| |
Collapse
|
38
|
Abstract
In 1996, a citizens group in Nogales, Arizona, reported to the Arizona Department of Health their concerns about a possible excess prevalence of systemic lupus erythematosus (SLE) due to exposure to environmental contamination in the area. The authors conducted a two-phase study in which the objectives of phase I were to identify potential SLE cases and to determine the prevalence of SLE and the objectives of phase II were to identify potential risk factors associated with the development of SLE and to evaluate the possible association between SLE and environmental exposure to pesticides and inorganic compounds. Participants included 20 confirmed cases and 36 controls. The authors found the prevalence of SLE to be 103 cases per 100,000 population (95 percent confidence interval: 56, 149), two to seven times higher than the prevalence in the US population. They detected elevated levels of 1,1-dichloro-2,2-bis-(p-chorophenyl)ethylene and organophosphate metabolites among cases and controls. In both, levels were higher than the reference mean for the US population. The authors found no statistical association between elevated levels of pesticides and disease status. Their results show that the prevalence of SLE in Nogales is higher than the reported prevalence in the US population and that both cases and controls had past exposure to chlorinated pesticides and have ongoing exposure to organophosphates.
Collapse
Affiliation(s)
- L Balluz
- Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
| | | | | | | | | | | | | |
Collapse
|
39
|
De Guise S, Shaw SD, Barclay JS, Brock J, Brouwer A, Dewailly E, Fair PA, Fournier M, Grandjean P, Guillette LJ, Hahn ME, Koopman-Esseboom C, Letcher RJ, Matz A, Norstrom RJ, Perkins CR, Schwacke L, Skaare JU, Sowles J, St Aubin DJ, Stegeman J, Whaley JE. Consensus statement: Atlantic Coast Contaminants Workshop 2000. Environ Health Perspect 2001; 109:1301-2. [PMID: 11748039 PMCID: PMC1240514 DOI: 10.1289/ehp.011091301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Affiliation(s)
- S De Guise
- Department of Pathobiology, University of Connecticut, Storrs, Connecticut 06269-1712, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Brock J, Sauaia A, Ahnen D, Marine W, Schluter W, Stevens BR, Scinto JD, Karp H, Bratzler D. Process of care and outcomes for elderly patients hospitalized with peptic ulcer disease: results from a quality improvement project. JAMA 2001; 286:1985-93. [PMID: 11667935 DOI: 10.1001/jama.286.16.1985] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
CONTEXT Since publication in 1994 of guidelines for management of peptic ulcer disease (PUD), trends in physician practice and outcomes related to guideline application have not been evaluated. OBJECTIVES To describe changes in process of care that occurred in a quality improvement program for patients hospitalized with PUD and to evaluate associations between in-hospital treatment of PUD and 1-year rehospitalization for PUD and mortality in a subset of these patients. DESIGN, SETTING, AND PATIENTS Cohort study of 4292 sequential Medicare beneficiaries hospitalized at acute care hospitals with a principal diagnosis of PUD in 5 states (Colorado, Georgia, Connecticut, Oklahoma, and Virginia) in 1995 (baseline) and 1997 (remeasurement); outcomes were evaluated for 752 patients in Colorado. MAIN OUTCOME MEASURES Changes in rates of screening for Helicobacter pylori infection, treatment for H pylori infection, screening for nonsteroidal anti-inflammatory drug (NSAID) use, counseling about NSAID use; outcomes included rehospitalization for PUD and all-cause mortality within 1 year of discharge in Colorado. RESULTS Screening for H pylori infection increased significantly (12%-19% increase; P<.001) in each of the 5 states. Treatment of H pylori infection increased in each state and was significantly increased for the entire group of hospitalizations examined (8% increase overall; P =.001). Despite increased screening, detection of H pylori infection was less frequent than expected in every state, (13%-24%) and did not increase in any state. Screening for and counseling about NSAIDs did not significantly increase overall or in any state. In the Colorado cohort, the proportion of patients rehospitalized was unchanged in 1995 (8.9%) and 1997 (6.8%), and 124 patients (16%) in the combined 1995 and 1997 cohorts died within 1 year. Treatment for H pylori was not associated with a reduction in rehospitalization within 1 year (adjusted odds ratio [OR], 1.24; 95% confidence interval [CI], 0.65-2.36) or with a reduction in mortality (adjusted OR, 1.08; 95% CI, 0.68-1.71). Counseling about NSAID use was associated with a decrease in risk of 1-year rehospitalization for PUD (adjusted OR, 0.47; 95% CI, 0.22-0.99) and risk of all-cause mortality (adjusted OR, 0.44; 95% CI, 0.26-0.75). CONCLUSIONS This quality improvement program for elderly patients with PUD resulted in increased screening for H pylori and increased treatment of H pylori infection but no change in counseling about NSAID use. However, with the low prevalence of H pylori detected, treatment of H pylori infection was not associated with a reduction in repeat hospitalization for PUD or subsequent mortality, whereas counseling about the risks of using NSAIDs was associated with a reduction in the risk of both outcomes.
Collapse
Affiliation(s)
- J Brock
- Colorado Foundation for Medical Care, 2851 S Parker Rd, Suite 1000, Aurora, CO 80014-2713, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Walzel H, Blach M, Neels P, Schulz U, Wollenhaupt K, Brock J. The B-chain of mistletoe lectin I efficiently stimulates calcium signaling in human Jurkat T-cells. Immunol Lett 2001; 78:57-66. [PMID: 11672588 DOI: 10.1016/s0165-2478(01)00238-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Mistletoe lectin I (ML I), a heterodimeric disulfide-linked type II ribosome inactivating protein, exhibits immunomodulatory potency in stimulating the cytokine release in vitro and in vivo. However, data concerning early activation events in T-cells induced by ML I and its A and B chain preceding cytokine secretion and the receptors involved are of limited availability. Here we show by flow cytometric measurements that human T-lymphoblastoid Jurkat cells express surface glycoprotein receptors for ML I. One of which is shown to be the CD2 antigen involved in a variety of T-cell signaling events. The lectin induces in Jurkat T-cells an increase of the cytosolic calcium concentration ([Ca(2+)](i)) consisting of both, the transient release of Ca(2+) from internal stores and a sustained influx of extracellular Ca(2+). Studies with isolated A- and B-chains provided evidence that the lectin-induced increase in [Ca(2+)](i) is mediated by ML IB. The ML I and ML IB stimulated cellular calcium responses are inhibited by saccharidic competitors. In transiently transfected E6.1 cells ML IB stimulated the expression of the luciferase reporter construct pNFAT-TA-Luc that is activated through the nuclear factor of activated T-cells (NFAT). The ML IB stimulated expression of the reporter luciferase (Luc) is completely inhibited by cyclosporin A (0.2 microM) and by FK 506 at 0.05 microM. Pretreatment of Jurkat E6.1 cells with 1-deoxymannojirimycin (dMJ), an inhibitor of cis-Golgi alpha-mannosidase I, strongly reduced cell binding of ML IB-FITC and the ML IB induced calcium response. Benzyl-alpha-GalNAc, an inhibitor of O-linked glycosylation, has slightly decreasing effects in ML IB-FITC binding and was without effects on the lectin stimulated increase in [Ca(2+)](i). Inhibition of the lectin induced calcium responses by cholera toxin and by inhibitors of protein kinases as well as the absence of calcium responses in CD3- and CD45- Jurkat T-cell clones suggest that ML IB has the potency to induce early T-cell activation events.
Collapse
Affiliation(s)
- H Walzel
- Institute of Medical Biochemistry and Molecular Biology, University of Rostock, Schillingalle 70, D-18057 Rostock, Germany
| | | | | | | | | | | |
Collapse
|
42
|
Bittorf T, Büchse T, Sasse T, Jaster R, Brock J. Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal 2001; 13:673-81. [PMID: 11495725 DOI: 10.1016/s0898-6568(01)00189-9] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The transcription factor nuclear factor kappa B (NF-kappaB) has been implicated in the regulation of genes mainly involved in inflammation and immune response. We analysed the role of NF-kappaB in signalling pathways induced by the hematopoietic growth factor erythropoietin (EPO). Our data, obtained by electrophoretic mobility shift assays (EMSA) and reporter gene assays, show that the intracellular domain of the EPO receptor (EPOR) transmits signals leading to the activation of NF-kappaB. Studies employing an inhibitor specific for the EPOR-associated tyrosine kinase JAK2 suggest that JAK2-dependent pathways are not involved. The induction of an NF-kappaB-triggered reporter gene construct was inhibited by cotransfection of dominant negative forms of the src kinase Lyn, but not by dominant negative JAK2. Using epidermal growth factor (EGF)/EPOR hybrids containing mutant forms of the EPOR intracellular domain, we were able to further define the critical structures for the induction of NF-kappaB. The data show that although the activity of JAK2 seems to be dispensable, its association to the receptor, as well as the phosphorylation of membrane proximal tyrosine residues, are essential. Furthermore, the functional analysis of different receptor forms revealed a correlation of the abilities to induce NF-kappaB activity and to generate antiapoptotic signals.
Collapse
Affiliation(s)
- T Bittorf
- Institute of Medical Biochemistry and Molecular Biology, Medical Faculty, University of Rostock, Schillingallee 70, PF100888, 18055 Rostock, Germany.
| | | | | | | | | |
Collapse
|
43
|
Heinig J, Wilhelm S, Müller H, Briese V, Bittorf T, Brock J. Determination of cytokine mRNA-expression in term human placenta of patients with gestational hypertension, intrauterine growth retardation and gestational diabetes mellitus using polymerase chain reaction. Zentralbl Gynakol 2001; 122:413-8. [PMID: 11005132 DOI: 10.1055/s-2000-10606] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
OBJECTIVE Our objective was to test the hypothesis, that pregnancy-related diseases are going along with changes in cytokine mRNA-expression at the placental site, either as a part of a pathological process or in connection with regulatory mechanisms induced by disturbances at the feto-maternal interface resulting from previous pathological changes--in the sense of counterregulation. MATERIAL AND METHODS The cytokines chosen for this investigation are known to 1.) be expressed in the human placental tissue, 2.) to be involved in immunological processes and 3.) the regulation of growth and differentiation processes of different cell types of the placenta or decidua, 4.) to play a role in the angiogenesis at the feto-placental interface and 5.) to be involved in pathological processes in other human diseases. 32 samples derived from term human placentas were examined for messenger RNA levels of interleukin 1 alpha (II-1 alpha), tumor necrosis factor-alpha (TNF-alpha), platelet derived growth factor-A chain (PDGF-A), platelet derived growth factor-B chain (PDGF-B), and platelet derived growth factor receptor (PDGF-R) using a semiquantitative reverse transcriptase (RT) polymerase chain reaction (PCR) protocol. To calibrate samples in our procedure, beta-actin mRNA (messenger ribonucleic acid) known as a "house keeping" gene was proven to be constantly expressed. The sample-groups consisted of normal pregnancies (n = 8), gestational hypertension (GH, n = 7), intrauterine growth retardation (IUGR, n = 6), gestational diabetes mellitus (GDM, n = 5), and gemini (n = 3 x 2). RESULTS Throughout the 32 samples, a significant correlation between PDGF-A and PDGF-R expression, PDGF-A and TNF-alpha expression was stated (p = 0.007). Compared with the pattern of expression in normal placentas, placentas of growth retarded pregnancies had higher Il-1 alpha mRNA (p = 0.016), PDGF-A (p = 0.029) and PDGF-B (p = 0.001) levels. The samples of the gestational hypertension group and placentas of patients with gestational diabetes displayed a significantly stronger PDGF-R mRNA signal (p = 0.0029 and p = 0.008). CONCLUSIONS Though these marked differences in cytokine mRNA levels between clinical groups were statistically proven, clear correlation of these differences with clinical data was not found.
Collapse
Affiliation(s)
- J Heinig
- Biochemical Institute of the University of Rostock.
| | | | | | | | | | | |
Collapse
|
44
|
Risch K, Strebel HP, Joshi RK, Lutz J, Brock J, Asadullah K, Volk H, Lehmann M. Methyl hydrogen fumarate inhibits acute and chronic rejection in rat kidney transplantation models. Transplant Proc 2001; 33:545-6. [PMID: 11266950 DOI: 10.1016/s0041-1345(00)02134-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- K Risch
- Institute for Medical Biochemistry and Molecular Biology, Med Faculty, University Rostock, Rostock, Germany
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Schröder G, Hammer M, Risch K, Flügel A, Brock J, Lehmann M, Ritter T, Volk HD. Visualization of alloantigen-specific, EGFP-engineered T lymphocytes in a rat kidney transplantation model. Transplant Proc 2001; 33:607-8. [PMID: 11266981 DOI: 10.1016/s0041-1345(00)02165-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- G Schröder
- Institute of Medical Biochemistry and Molecular Biology, University of Rostock, Max Planck Institute for Neurobiology, Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Claus R, Bittorf T, Walzel H, Brock J, Uhde R, Meiske D, Schulz U, Hobusch D, Schumacher K, Witt M, Bartel F, Hausmann S. High concentration of soluble HLA-DR in the synovial fluid: generation and significance in "rheumatoid-like" inflammatory joint diseases. Cell Immunol 2000; 206:85-100. [PMID: 11161440 DOI: 10.1006/cimm.2000.1729] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
In the search for its role in inflammatory joint diseases, soluble HLA-DR (sHLA-DR) was quantitated in 72 synovial fluids (SF) by a newly established immunoenzyme assay. Unlike other soluble receptors which accumulated only moderately (sCD25, sCD4) or negligibly (sHLA class I, sCD8) in the SF, SF sHLA-DR levels exceeded serum levels by up to 3 orders of magnitude and varied disease dependently from "control" values (traumatic synovitis and osteoarthritis: 9.9 +/- 6.1 ng/ml). Clear-cut different SF sHLA-DR values in HLA-DR-associated "rheumatoid-like" (136.5 +/- 130.0 ng/ml) vs HLA-B27-associated "spondylarthropathy-like" arthritic forms (28.4 +/- 29.1 ng/ml) were most significant comparing oligoarticular juvenile chronic arthritis type I (147.6 +/- 112.6 ng/ml) and type II (3.3 +/- 1.1 ng/ml), thus offering a new classification marker. Also ex vivo, large amounts of sHLA-DR were released spontaneously by SF mononuclear cells and found to be related to the T-cell activation state. SF sHLA-DR may be shed in large complexes or micelles, as it eluted mainly at >450 kDa on gel filtration. Western blotting revealed that the majority of SF sHLA-DR consisted of full-length alpha- and beta-chains. Minor fractions of smaller sized antigens seemed to be generated by proteolytic cleavage rather than by alternative splicing, since only minute amounts of HLA-DRB mRNA lacking the transmembrane exon could be amplified by RT-PCR. Distinct forms of high-dose sHLA-DR, able to provoke rather than to suppress T-cell responses, are discussed as contributing to some HLA-DR disease association.
Collapse
Affiliation(s)
- R Claus
- Institute of Immunology, University Rostock, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Bittorf T, Sasse T, Wright M, Jaster R, Otte L, Schneider-Mergener J, Brock J. cDNA cloning and functional analysis of a truncated STAT5a protein from autonomously growing FDCP-1 cells. Cell Signal 2000; 12:721-30. [PMID: 11152957 DOI: 10.1016/s0898-6568(00)00112-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The transcription factor STAT5 is activated by multiple hematopoietic cytokine receptors and has been implicated in the induction of cellular processes such as differentiation, proliferation and antiapoptotic activities. Here, we report cloning of the cDNA and characterization of a mutant STAT5a protein that is expressed in interleukin-3 (IL-3)-independently growing FDCP-1 cells. Analysis of the cDNA revealed a deletion of both the transactivation and the SH2 domains. Stable expression of the protein in parental IL-3-dependent cells results in elevated DNA binding activity of wild type (WT)-STAT5 in the nucleus, enhanced growth rates and a reduced susceptibility to undergo apoptosis after withdrawal of IL-3. Although the protein is not present in DNA/protein complexes in the nucleus, we observed pronounced effects on IL-3-induced signal transduction. The results suggest competition of the mutant protein with cytosolic mechanisms regulating STAT5 activity. In conclusion, the data support the hypothesis of an involvement of STAT5 in mitogenic and antiapoptotic signaling.
Collapse
Affiliation(s)
- T Bittorf
- Medical Faculty, Institute of Medical Biochemistry, University of Rostock, Schillingallee 70, PF100888, 18055, Rostock, Germany.
| | | | | | | | | | | | | |
Collapse
|
48
|
Bittorf T, Jaster R, Soares MJ, Seiler J, Brock J, Friese K, Müller H. Induction of erythroid proliferation and differentiation by a trophoblast-specific cytokine involves activation of the JAK/STAT pathway. J Mol Endocrinol 2000; 25:253-62. [PMID: 11013351 DOI: 10.1677/jme.0.0250253] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Pregnancy is characterized by increased erythropoiesis within maternal and fetal compartments. The placenta has been shown to produce factors that stimulate erythropoiesis but convincing evidence for placental production of erythropoietin (EPO) is still lacking. Prolactin-like protein E (PLP-E) was recently found to stimulate expression of the adult beta major globin gene in mouse erythroleukemia cells. Here we demonstrate that PLP-E transiently expressed in COS-7 cells stimulates proliferation and erythroid differentiation of murine and human erythroid progenitor cell lines. Electrophoretic mobility shift assays were used to show the activation of STAT5 by PLP-E in the human erythroid cell line TF1. Furthermore, we compared the effects of PLP-E on murine myeloid FDCP1 cells which do not express EPO receptors (EPORs) with effects on cells genetically engineered to express functional EPORs. We provide evidence that PLP-E-dependent proliferation and STAT5 activation is independent of the expression of the EPOR. Taken together, these data suggest that PLP-E acts on specific receptors of erythroid-committed murine and human cells by the activation of intracellular signaling pathways promoting cell growth and differentiation.
Collapse
Affiliation(s)
- T Bittorf
- Institute of Medical Biochemistry, University of Rostock, Doberaner Str. 142, 18057 Rostock, Germany
| | | | | | | | | | | | | |
Collapse
|
49
|
Baughman R, Sandow P, Brock J. Diagnostic quiz #44. Case no. 1. Leukemic infiltrate.. Todays FDA 2000; 12:20-2. [PMID: 11404952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- R Baughman
- University of Florida Oral and Maxillofacial Pathology and Oncology, USA
| | | | | |
Collapse
|
50
|
Schröder G, Risch K, Nizze H, Kolls J, Reinke P, Brock J, Lehmann M, Volk HD, Ritter T. Immune response after adenoviral gene transfer in syngeneic heart transplants: effects of anti-CD4 monoclonal antibody therapy. Transplantation 2000; 70:191-8. [PMID: 10919599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
BACKGROUND E1-deleted adenoviral vectors are frequently used for in vivo gene therapy. However, gene expression after adenovirus-(ad) mediated gene transfer is known to be transient due to the generation of an immune response against virus-infected cells. In this study, we asked whether an anti-CD4 mAb (RIB 5/2) treatment may improve the gene transfer into rat cardiac grafts. METHODS We injected recombinant ad-constructs encoding for Escherichia coli beta-gal into syngeneic rat heart transplants via the proximal aorta. One-half of the recipients of genetically modified grafts received the anti-CD4 mAb RIB 5/2, whereas the other half received no monoclonal antibody treatment. Genetically unmodified isografts without any treatment of the recipients were used as additional controls. At different time points hearts were harvested and analyzed for reporter gene expression, intragraft cellular infiltration, and cytokine gene expression (quantitative "real time" reverse transcriptase polymerase chain reaction). Serum samples were analyzed for anti-ad-Ig using enzyme-linked-immunosorbent-assay. RESULTS In control animals the beta-gal reporter gene expression slowly increased until day 7 and then declined. The immunohistological and reverse transcriptase polymerase chain reaction intragraft analyses revealed a strong inflammatory response (cellular infiltration, cytokine expression) in ad-transfected grafts that may explain the delayed expression and fast down-regulation of the transgene. Treatment with RIB 5/2 mAb resulted in a faster and prolonged reporter gene expression, reduced graft infiltration, reduced anti-ad-Ig titers and less interferon-gamma up-regulation. CONCLUSIONS Our results indicate that modulation of the anti-ad immune response using a nondepleting anti-CD4 mAb may increase the efficiency of ad-vectors for gene therapy in the transplant setting.
Collapse
Affiliation(s)
- G Schröder
- Institute of Medical Biochemistry and Molecular Biology, University Rostock, Department of Nephrology and Internal Care, Charité, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|